Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces it has named Robert Martell, M.D., Ph.D. to its Board of Directors.
Having been in the pharmaceutical industry for more than 20 years, Dr. Martell currently serves as Head of Research and Development, as well as previously serving on the Board of Directors for more than six years at Curis, Inc. He is also an attending physician at Tufts Medical Center in Boston. Previously, he has held management positions in numerous publicly traded and private companies, including Epi-Cure Pharmaceuticals, Tesaro, Inc., and Methylgene, Inc., as well as filling key roles at Big Pharma, including Bayer and Bristol-Meyers Squibb.
In addition, he served in multiple other top-tier academic hospitals, including Duke University, where he completed his internal medicine residency and oncology fellowship, as well as serving as an Assistant Professor and a Fellow in the Center for the Study of Aging and Human Development. He also served as adjunct Assistant Clinical Professor at Yale. Dr. Martell is widely published with an impressive array of articles in peer-reviewed medical journals. He received his medical training at Wayne State University School of Medicine, a Ph.D. in pharmacology from the University of Michigan and his Bachelor of Arts degree in chemistry from Kalamazoo College.
“Robert’s extensive industry experience and deep understanding of the issues associated with drug development, combined with his ongoing practice makes him an ideal board member for Indaptus. I look forward to collaborating with him to help guide the Company toward continued success,” stated Roger Pomerantz, M.D., chairman of Indaptus Therapeutics’ Board of Directors.
“As a practicing physician with deep oncology experience, and a long-time veteran of the pharmaceutical industry, we believe Robert is an ideal addition to our Board of Directors,” commented Jeffrey Meckler, Indaptus Therapeutics’ Chief Executive Officer. “As a clinical-stage company, we look forward to his input in our development programs and his perspective as we continue to explore our Decoy platform toward what we believe will be a novel approach to treating cancer.”
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and the associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria to produce a multiple TLR agonist Decoy platform, with expected reduced systemic toxicity, and ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy20 represents an antigen-agnostic technology that has produced in pre-clinical studies single agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established, antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas and non-Hodgkin’s lymphomas with standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. In those pre-clinical studies tumor eradication has been observed with Decoy products in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, non-steroidal anti-inflammatory drug or an approved targeted antibody. Combination-based tumor eradication produces innate and adaptive immunological memory, involves activation of both innate and adaptive immune cells and is associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling toxicology studies have demonstrated safe i.v. administration, with no sustained induction of hallmarks of cytokine release syndromes, possibly due to passive targeting to liver, spleen and tumor, followed by rapid elimination of the product. Indaptus products have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
This press release contains forward-looking statements with the meaning of the Private Securities Litigation Reform Act. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies, plans and prospects. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: our plans to develop and potentially commercialize its technology, the timing and cost of our planned investigational new drug application and any clinical trials, the completion and receiving favorable results in any clinical trials, Indaptus’ ability to obtain and maintain regulatory approval of any product candidate, our ability to protect and maintain its intellectual property and licensing arrangements, our ability to develop, manufacture and commercialize its product candidates, the risk of product liability claims, the availability of reimbursement, the influence of extensive and costly government regulation, and our estimates regarding future revenue, expenses capital requirements and the need for additional financing. More detailed information about the risks and uncertainties affecting us is contained under the heading “Risk Factors” included in our most recent Annual Report on Form 10-K filed with the SEC on March 21, 2022, and in other filings that we have made and may make with the Securities and Exchange Commission in the future. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.
Contact: [email protected]
Investor Relations Contact:
Scott Birkby (investors)
Jules Abraham (media)